Hydroxychloroquine Archives

A Rheumatologist Explains Why a Hydroxychloroquine Shortage Is Terrifying to Lupus and Rheumatoid Arthritis Patients

March 27, 2020

A Rheumatologist Explains Why a Hydroxychloroquine Shortage Is Terrifying to Lupus and Rheumatoid Arthritis Patients‘Hydroxychloroquine is a safe, effective, and inexpensive therapy

Healio Rheumatology – Updates

VIDEO: Investigating phenotypes of rheumatoid arthritis-associated interstitial lung disease

SAN DIEGO — In this Healio video, Jeffrey A. Sparks, MD, MMSc, highlighted studies from members of his group at Brigham and Women’s Hospital that were presented at ACR Convergence 2023.“Our group was lucky enough to have several presentations at ACR 2023,” said Sparks, an associate professor of medicine at Harvard Medical School and an associate program director of the Rheumatology Fellowship, director of Immuno-Oncology and Autoimmunity and director of the Joint Biology Consortium Human Biosamples Core at Brigham and Women’s Hospital.The first presentation he
VIDEO: Administering medication through the lymphatic system for rheumatoid arthritis

SAN DIEGO — In this Healio video, Jeffrey A. Sparks, MD, MMSc, discusses results from a proof-of-concept study that assessed the efficacy of administering medication for rheumatoid arthritis into the peripheral lymphatic systems.The findings were presented at ACR Convergence 2023.“This was only 10 patients,” said Sparks, an associate professor of medicine at Harvard Medical School and an associate program director of the Rheumatology Fellowship, director of Immuno-Oncology and Autoimmunity and director of the Joint Biology Consortium Human Biosamples Core at Brigham and Women’s
Booster COVID-19 vaccine dose protects against breakthrough infection in vasculitis

SAN DIEGO — Patients with primary systemic vasculitis who received a third or additional doses of a COVID-19 vaccine demonstrated a reduced risk for breakthrough infection, according to data presented at ACR Convergence 2023.“We know immunosuppression is a very important part of the management of patients with primary systemic vasculitis,” Michael Chen-Xu, MD, of theUniversity of Cambridge, in the United Kingdom, told attendees. “However, we know these patients are at high risk for contracting COVID-19. Also, we know that vaccine responses, particularly humoral
FDA testing finds hidden ingredients in products marketed for arthritis, pain

The FDA has advised consumers to exercise caution before using certain products promoted for arthritis and pain, as some have been found to contain hidden ingredients that may pose a significant health risk.According to an FDA release, testing found multiple products containing active drug ingredients not listed on the product labels. To protect consumers from unsafe products and help them be more aware of what they buy, the FDA has compiled a list of public notifications that includes a small fraction of the potentially dangerous products on the market.In November, the FDA added Himalayan